All In Biotech

Drug Trial Radar · NCT06567769

Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)

A Phase 1, Open-label, Ascending Dose Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Recombinant Human Heparan N-Sulfatase (rhHNS, GC1130A) Via Intracerebroventricular Access Device in Patients With Sanfilippo Syndrome Type A (MPS IIIA)

Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

9

Planned (sponsor's estimate)

Start

Nov 21, 2024

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
GC Biopharma CorpIndustry
Sponsor type
Industry
First posted
Aug 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of recombinant human heparan N-sulfatase (rhHNS, GC1130A) administered via intracerebroventricular access device in patients with Sanfilippo Syndrome Type A (MPS IIIA).

Conditions

  • Sanfilippo Syndrome Type A

Interventions

  • GC1130ADrug

    ICV injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidences and characteristics of adverse eventsTime frame: up to 108 weeks

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • UCSF Benioff Children's Hospital

    Oakland, California

  • University of Minnesota

    Minneapolis, Minnesota

  • Samsung Medical Center

    Seoul, South Korea

  • Ajou University Medical Center

    Suwon, Gyeongi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.